naltrexone has been researched along with maraviroc in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (83.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Arnatt, CK; Dever, SM; El-Hage, N; Hauser, KF; Jacob, JC; Selley, DE; Yuan, Y; Zhang, Y | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Arnatt, CK; El-Hage, N; Falls, BA; Hauser, KF; Knapp, PE; Masvekar, RR; Nicola, AV; Raborg, TJ; Selley, DE; Yuan, Y; Zhang, Y | 1 |
Barreto-de-Souza, V; Hauser, KF; Huang, B; Kang, G; Knapp, PE; Li, M; Nassehi, N; Selley, DE; Wang, H; Zhang, Y; Zheng, Y | 1 |
Arnatt, CK; Dever, SM; El-Hage, N; Hauser, KF; Podhaizer, EM; Zhang, Y | 1 |
1 review(s) available for naltrexone and maraviroc
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for naltrexone and maraviroc
Article | Year |
---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor CCR5 Heterodimers: Binding Affinity versus Functional Activities.
Topics: | 2013 |
Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.
Topics: Anti-HIV Agents; Cyclohexanes; Dimerization; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Ligands; Maraviroc; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Naltrexone; Receptors, CCR5; Receptors, Opioid, mu; Structure-Activity Relationship; Triazoles | 2016 |
Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity.
Topics: Analgesics, Opioid; Anti-HIV Agents; Binding Sites; Dimerization; Drug Design; HIV-1; Humans; Leukocytes, Mononuclear; Ligands; Maraviroc; Molecular Docking Simulation; Molecular Dynamics Simulation; Naltrexone; Phytohemagglutinins; Protein Binding; Receptors, CCR5; Receptors, Opioid, mu; Virus Internalization | 2021 |
A novel bivalent HIV-1 entry inhibitor reveals fundamental differences in CCR5-μ-opioid receptor interactions between human astroglia and microglia.
Topics: Astrocytes; Cells, Cultured; Cyclohexanes; Genes, Reporter; HIV Fusion Inhibitors; HIV-1; Humans; Luciferases; Maraviroc; Microglia; Naltrexone; Receptors, CCR5; Receptors, Opioid; Triazoles; Virus Internalization | 2013 |